Why Lab‑Expanded MSCs Cryopreserved After Expansion Are Superior
At Stem Cell Therapy Experts (SCTE), Dr. Yi Song champions a stem cell method rooted in quality-first MSC preparation: expanding umbilical cord‑derived mesenchymal stem cells (MSCs) in a lab and cryopreserving only after rigorous testing. This strategic approach delivers consistent, high‑potency stem cell therapies—unlike most U.S. clinics that freeze cells immediately post-isolation.
Lab Expansion Ensures Healthier MSCs
Many clinics follow FDA regulations by isolating and immediately freezing unexpanded MSCs from umbilical cords. While legally compliant, this method stresses cells through mechanical and enzymatic processing and deprives them of recovery time. Survival rates often hover just above 70% viability, with impaired function.
Dr. Yi, however, has her teams culture cord‑derived MSCs to healthy proliferation, reaching around 94% viability before freezing. After thawing, these MSCs retain ≥85% viability—far exceeding common benchmarks. This method selects for fit, resilient cells primed for regenerative and immunomodulatory performance.
Science Backing MSC Expansion
Lab‑expanded umbilical MSCs consistently outperform freshly isolated cells. A 2021 study highlighted that expanded umbilical cord MSCs maintain stronger metabolic activity, secrete more paracrine factors, and display better homing abilities than minimally processed cells (expanded umbilical cord MSCs).
Crucially, Dr. Yi’s process includes testing for genetic stability via STR analysis—ensuring no mutations during expansion, a check absent in many commercial labs.
Cryopreserving After Expansion: A Tactical Edge
Dr. Yi states, “Freezing cells post-expansion—not immediately after isolation—preserves their integrity.” Flash-freezing uncultured cells locks in stress-induced damage, undermining their therapeutic utility. SCTE’s post-expansion freezing allows cells time to stabilize and recover, blending the accessibility of cryostorage with the efficacy of fresh cells.
